Recent studies have revealed that IL-25 treatment reduces neuroinflammation and EAE disease severity [37,139], suggesting that IL-25 and IL-17, despite being members of the same cytokine family, play opposing roles in the pathogenesis of MS. This evidence concerns the gene IL25 and myeloid sarcoma.